Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qiangli Pipalu Lianmi is a Traditional Chinese Medicine (TCM) oral syrup developed and manufactured by Huabao Pharmaceutical. It is formulated as an antitussive and expectorant for the relief of cough and respiratory symptoms. The Qiangli (strong) designation typically indicates a formulation containing poppy capsule (Papaveris Pericarpium) for enhanced cough suppression, alongside other herbal ingredients such as loquat leaf (Eriobotrya japonica), Stemona root, and Menthol. The Lianmi suffix refers to the use of refined honey as a base, which acts as a demulcent. It is used to treat coughs associated with phlegm-heat obstructing the lungs, characterized by frequent coughing and thick sputum.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qiangli Pipalu Lianmi.